Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.41 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL319980 | 1.00 | CPB2 (0.53) | CPB2CA2LMNAZDHHC7CA1 | |
| Methyl Alcohol SCHEMBL7668985 | 0.98 | CPB2 (0.51) | CPB2CA2LMNAZDHHC7CA1 | |
| Ammonia Solution, Strong SCHEMBL5121318 | 0.98 | CPB2 (0.51) | CPB2CA2LMNAZDHHC7CA1 | |
| SCHEMBL3845206 | 0.98 | CPB2 (0.50) | CPB2CA2LMNAZDHHC7CA1 | |
| Acetic Acid SCHEMBL3260364 | 0.95 | CPB2 (0.49) | CPB2CA2LMNAZDHHC7CA1 | |
| Ethyl Acetate SCHEMBL1279632 | 0.93 | CPB2 (0.47) | CPB2CA2LMNAZDHHC7CA1 | |
| Ethyl Acetate SCHEMBL5064725 | 0.93 | CPB2 (0.47) | CPB2CA2LMNAZDHHC7CA1 | |
| SCHEMBL3176263 | 0.92 | CA2 (0.52) | CPB2CA2CA1KDM4EDUSP3 | |
| Ethyl Acetate SCHEMBL17005456 | 0.90 | CPB2 (0.45) | CPB2CA2LMNAZDHHC7GRIK1 | |
| Ethyl Acetate SCHEMBL17699277 | 0.90 | CPB2 (0.45) | CPB2CA2LMNAZDHHC7GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1035 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782986-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-10 | — | — | EP | disclosed |
| CN-113307772-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-4389750-A1 | NUCLEOSIDE DERIVATIVES AND PRODRUGS THEREOF HAVING VIRAL GROWTH INHIBITORY ACTION | Shionogi & Co., Ltd. (JP) | 2024-06-26 | — | — | EP | disclosed |
| US-11964943-B2 | 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of Stat3 pathway activity and uses thereof | KIAKOS KONSTANTINOS (AT) | 2024-04-23 | — | — | US | disclosed |
| CN-112313210-B | Photochromic indeno-fused naphthopyran compounds with reduced temperature dependence | 光学转变有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-111918863-B | Heterocyclic compounds | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| US-20230117295-A1 | NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-04-20 | — | — | US | disclosed |
| US-11584737-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-21 | — | — | US | disclosed |
| WO-2023014049-A1 | NOVEL PYRROLOPYRIMIDINE DERIVATIVE, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING METABOLIC LIVER DISEASE | 한국화학연구원 | 2023-02-09 | — | — | WO | disclosed |
| WO-2023278827-A1 | 3-IODOPROPYL-1,2,3-TRIAZOL-1-YL, 3-BROMOPROPYL-1,2,3-TRIAZOL-1-YL, AND DERIVATIVES FOR USES IN LABELING | EMORY UNIVERSITY (US) | 2023-01-05 | — | — | WO | disclosed |
| US-4351843-A | LOWERING BLOOD GLUCOSE | PFIZER INC. (US) | 1982-09-28 | — | — | US | disclosed |
| US-4347187-A | Process for preparing 5-aroyl 1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acids and novel intermediates therein | SYNTEX (U.S.A.) INC. (US) | 1982-08-31 | — | — | US | disclosed |
| US-4347186-A | Process for preparing 5-aroyl 1,2-dihydro-3-H pyrrolo[1,2-a]pyrrole-1-carboxylic acids and novel intermediates therein | SYNTEX (U.S.A.) INC. (US) | 1982-08-31 | — | — | US | disclosed |
| US-4282242-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
| US-4238622-A | D,L-2-Amino-4-(2-aminoethoxy)-trans-but-3-enoic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 1980-12-09 | — | — | US | disclosed |
| US-4058551-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1977-11-15 | — | — | US | disclosed |
| US-4042606-A | PROSTAGLANDIN ENANTIOMORPHS | THE UPJOHN COMPANY (US) | 1977-08-16 | — | — | US | disclosed |
| US-3962289-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
| US-3932486-A | GASTRIC SECRETION INHIBITORS, ANTISPASMODIC, ANTIASTHMATIC, HYPOTENSIVE | THE UPJOHN COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
| US-3931281-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117295-A1 | NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORS | CDK1, CDK12, CDK15 | CPB2 1265/4885CA2 1739/4885LMNA 1082/4885 |
| US-11964943-B2 | 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of Stat3 pathway activity and uses thereof | STAT3, JAK2, STAT6 | CPB2 3524/4885CA2 2894/4885LMNA 3396/4885 |
| US-11584737-B2 | Heterocyclic compound | CDK12, CDK1, CDK15 | CPB2 1186/4885CA2 1518/4885LMNA 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.